First Patient Dosed in Japanese Prostate Cancer Imaging Study
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product, Illuccix®.
Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging
Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.
Telix at ANZSNM Annual Scientific Meeting
Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live and local.
Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses
Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
Telix and Monrol Expand Alliance to Include Lutetium Supply
Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR products.
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced prostate cancer.
Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region
Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.
Telix Pharmaceuticals Appoints Richard Valeix as EMEA President
Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA).
Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement
Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.
Japanese Renal Cancer Imaging Trial Meets Study Objectives
Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese patients.